Somatic mutation of the FLT3 gene as an internal tandem duplication (ITD) of the juxtamembrane domain-coding sequence causes constitutive tyrosine phosphorylation and activation. Tumor-specific DNA has been documented in the sera of patients with solid tumors even when it is in an early stage. We compared the detection of FLT3 ITD in DNA extracted from cells of bone marrow (BM) aspirations with DNA extracted from peripheral blood (PB) plasma in patients newly diagnosed with acute myeloid leukemia (AML; 85 patients), myelodysplastic syndrome (MDS; 16 patients), and acute lymphocytic leukemia (ALL; 16 patients). FLT3 ITD was detected in 18 (21%) AML samples and in one (6%) MDS sample in both cellular and plasma DNA but in none of the ALL samples. Hemizygous/homozygous FLT3 ITD was detected in five (28%) of the FLT3 ITD-positive AML using plasma DNA, whereas only four of these cases showed hemizygous/homozygous FLT3 ITD using cellular DNA. The presence of FLT3 ITD was associated with significantly shorter survival (P = 0.02) when only patients younger than 50 years of age (48 AML+MDS patients) were considered. This finding was independent of cytogenetics in this age group. However, patients with the FLT3 ITD hemizygous/homozygous phenotype had even shorter survival (P = Ͻ0.001). As expected, the presence of FLT3 ITD correlated with higher white blood cell (WBC) counts. These data demonstrate that plasma DNA is a reliable alternative resource for detecting FLT3 ITD, especially the hemizygous/homozygous genotype. Furthermore, the data derived from this study support the notion that the presence of FLT3 ITD in conjunction with the absence of the wild-type FLT3 allele predicts an especially poor prognosis for patients with AML.
Introduction
FLT3 is a class III receptor tyrosine kinase that is structurally related to the receptors for the platelet-derived growth factor (PDGF), colony-stimulating factor (CSF), and Kit ligand (KL). [1] [2] [3] [4] [5] It is expressed on murine hematopoeitic stem cells and when activated by its ligand (FL) supports survival, proliferation, and differentiation of primitive hematopoeitic progenitor cells. [6] [7] [8] [9] [10] [11] [12] [13] The human gene for FLT3 maps to human chromosome 13q12-q13. 14, 15 Somatic mutation of the FLT3 gene is an internal tandem duplication (ITD) in the juxtamembrane domain-coding sequence of the gene which was found in about 20% of AML and in a small number of MDS cases. 11, [16] [17] [18] [19] [20] [21] [22] [23] The duplicated sequence belongs to exon 11 but sometimes involves intron 11 and exon 12. 15, 20, 24 A recent study by Whitman et al 25 demonstrated that some cases have complete deletion of one allele and ITD in the second allele. This hemizygous genotype for ITD was associated with a sub- stantially shorter survival. FLT3 mutations are frequently associated with leukocytosis. 9 Representative leukemic cells from PB or BM tissue are frequently mixed with normal cells making it difficult to detect the FLT3 mutation, particularly the hemizygous mutation. Tumor specific DNA has been documented in the sera of patients with solid tumors even when the tumor burden appears small. [26] [27] [28] The purpose of this study was to compare the detection of FLT3 ITD in DNA extracted from PB plasma samples with that of DNA extracted from cells obtained from BM tissue and the impact of the presence of FLT3 ITD on prognosis.
Materials and methods

Patients and samples
DNA was extracted from cells obtained from BM tissues and PB plasma of 117 patients newly diagnosed with AML, MDS, or ALL. All samples were collected under an Institutional Review Board-approved protocol and signed informed consent was obtained from patients. The diagnosis was established using standard morphologic, immunologic, and molecular evaluations. Cytochemical staining for myeloperoxidase, non-specific esterase, and periodic acid Schiff (PAS) was performed when appropriate. Complete immunophenotyping and cytogenetics were performed on all patients. The EDTA PB samples were drawn on the same day as BM samples. The samples were then spun down, and plasma was collected and frozen until the plasma DNA was extracted.
DNA extraction
Cellular DNA from BM aspirates was extracted using the standard phenol/chloroform extraction procedure as described elsewhere. 29 Plasma DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. Briefly, 400 l of thawed plasma was added to a mixture of 40 l protease and 400 l AL buffer (Qiagen) and incubated at 56°C for 30 min. Then 400 l of 100% ethanol was added to the mixture followed by the elution of the mixture using the QIAamp spin column in two equivalent increments. The column was then washed with three different buffers (AW1, AW2, AE; Qiagen). DNA was eluted to a volume of 50 l with the last buffer.
FLT3 tandem repeat PCR testing
The DNA products from both the cells and plasma were analyzed for the presence of ITD using a modified polymerase chain reaction (PCR) process. 9 The primer set used to detect exon 11 was synthesized by Sigma Genosys (The Woodlands, TX, USA) using the following sequences: AML-11 forward (5′-CAATTTAGGTATGAAAGCC-3′) and AML-11 reverse (5′-CAAACTCTAAATTTTCTCT). The reverse primer was labeled with a Fam fluorescent marker. PCR was performed in a 25 l reaction volume containing 50 ng of genomic DNA by preheating to 95°C for 5 min and then using a 10-cycle amplification of 95°C for 1 min, 50°C for 1 min, and 72°C for 1 min. This was followed by a 25-cycle amplification of 95°C for 1 min, 47°C for 0.5 min, and 72°C for 1 min. These cycles were followed with a final extension of 72°C for 10 min. PCR products from the cells were diluted with water at a ratio of 1:20 but the plasma DNA PCR products were not. One microliter of the PCR product was used for quantitative genescan analysis on ABI Prism 310 and 3100 genetic analyzers (Applied Biosystems, Foster City, CA, USA). Genescan analysis software (Applied Biosystems) was used to measure the peak areas and height of the FLT3 alleles. The wild-type allele was always detected at around 129 bp, and the ITD allele varied in size from 149 bp to 240 bp.
Loss of heterozygosity determination
Loss of heterozygosity (LOH) was determined using three different microsatellite markers for chromosome 13: D13S175, D13S218 and D13S1265. PCR was done on the BM cells, PB plasma, and CD3
+ cells (as a control) of the five patients showing the hemizygous/homozygous trait. LOH analysis was done on an ABI Prism 3100 genetic analyzer.
Statistical analysis
Correlation and association analyses were done using the Spearman rank test. Group comparison was performed using Kruskall-Wallis or Wilcoxon tests. The Kaplan-Meier test was used to analyze survival. All clinical data were collected from patient records and organized in the leukemia clinical database.
Results
ITD detection and determination of hemizygous and homozygous phenotype
As predicted, the wild-type FLT3 band was seen in all samples as a 129 bp band. The ITD bands were seen as larger DNA fragments and varied in size between 149 and 240 bp ( Figure  1 ). The ITD bands were expected to have less intensity compared with the wild-type band due to their size and the lower efficiency of PCR amplification. All BM samples analyzed had less than 100% leukemic cells and normal cells contributing to the wild-type FLT3 band. Therefore, when a case showed an ITD band with an intensity stronger than the wild-type, this case was considered either homozygous for ITD (two alleles detected and both had ITD) or hemizygous (one allele deleted and one had ITD) (Figure 1 ). One case showed two discrete bands for ITD that were different sizes. This case was classified as homozygous for the presence of ITD (Figure 1 ). All samples with evidence of mutation were repeated two or three times to confirm the findings and rule out PCR artifact. Cases that were classified as homozygous or hemizygous with an Leukemia ITD band stronger in intensity than the wild-type band were tested for LOH using three microsatellite markers (D13S218, D13S1265 and D13S175) to confirm the deletion of the second allele (hemizygous). Of the four homozygous or hemizygous cases, only two showed LOH confirming the hemizygous phenotype. These LOH were deleted in D13S1265 in both cases. The possibility remains that the second allele is deleted but the deletion does not encompass the three microsatellite markers used here. The second possibility is that the two alleles in the three cases that show no LOH have identical ITD (homozygous) in both alleles.
Better detection of FLT3 ITD in PB plasma as compared to BM cells
We studied 117 newly diagnosed leukemic cases, including 85 AML, 16 MDS and 16 ALL, using both BM cell DNA and PB plasma DNA. All FLT3 ITD mutations detected in BM cells were also detected in PB plasma. All plasma DNA showed analyzable DNA. Both PB plasma and BM cell DNA showed ITD in 18 (21%) of the AML cases, one (6%) of the MDS cases, and none of the ALL cases. However, five (28%) of the FLT3 mutant AML cases met the criteria for hemizygous or homozygous phenotype in plasma DNA (significantly stronger ITD band in four cases and two ITD bands in one case) ( Table 1 ) (Figure 2 ). In contrast, only four of these cases (three with a stronger ITD band and one with two ITD bands) qualified for hemizygous or homozygous phenotype when BM cellular DNA was evaluated. Furthermore, the intensity of the ITD bands in all cases with positive ITD was significantly stronger in plasma DNA samples when compared with their BM cellular DNA counterpart (P = 0.009 by the Wilcoxon matched pairs test). This made it easier to detect the mutations and distinguish them from PCR artifacts.
Clinical correlation
The general characteristics of AML and MDS patients are described in Table 2 . These characteristics are representative of our population of AML/MDS patients. The number of patients studied here is too small and for better clinical correlation, a large number of patients needs to be studied. In our patients, there was no clinical correlation between FLT3 ITD and overall survival or event-free survival in AML and MDS patients when patients of all ages were considered. However, FLT3 ITD was associated with a significantly shorter overall survival (P = 0.01) and event-free survival (P = 0.04) in young (age Ͻ50 year) AML and MDS (n = 48) patients (Figure 3 ). In fact, in this age group, multivariate analysis showed that FLT3 ITD was predictive of overall survival independent of cytogenetics. The number of cases is too small to evaluate survival in patients with intermediate cytogenetic abnormalities. As reported previously, patients hemizygous or homozygous for FLT3 ITD had an even shorter overall survival duration with a P value of Ͻ0.001 in the same age group reflecting the importance of detecting the hemizygous or homozygous phenotype. In this analysis we combined AML and MDS patients because most of the MDS patients had advanced disease and all were treated as AML. In fact, 12 of the 16 MDS patients had refractory anemia with excess blasts in transformation (RAEB-T) and with the new World Health Organization (WHO) classification should be classified as AML. Also as expected, the presence of FLT3 ITD correlated with higher WBC counts (P = 0.002), and the highest mean WBC count was found in the hemizygous/homozygous genotype ( Figure  4 ). There was no correlation between FLT3 ITD and poor cytogenetics or the presence or absence of antecedent hematologic disease.
Discussion
FLT3 ITD is a somatic mutation in the juxtamembrane region of the FLT3 gene and is believed to cause constitutive activation of the protein. [16] [17] [18] [19] The presence of FLT3 ITD in one allele and its deletion in the second allele has been recently demonstrated in some cases of AML. 25 Because pure tumor cells are not easily obtained from BM aspiration samples, the use of plasma from PB samples is one possible alternative for the detection of FLT3 ITD. The presence of tumor-specific DNA in plasma of patients with solid tumors has been reported in numerous studies. [26] [27] [28] We have demonstrated, using LOH, that plasma DNA is better than morphology and blast count in detecting residual disease in AML and MDS patients (Rogers et al, submitted) . Here, we compared the detection of FLT3 ITD in DNA extracted from cells obtained from BM tissue and DNA extracted from PB plasma from the same 117 patients newly diagnosed patients with AML, MDS, and ALL. FLT3 ITD detection in DNA extracted from PB plasma was more reliable than that in BM cell DNA. In one patient a hemizygous or homozygous phenotype was detected only in PB plasma DNA and not in BM cell DNA. The relative intensity of the ITD bands compared with wild-type peaks were significantly higher in PB plasma DNA than BM Cell DNA. These data suggest that plasma is more enriched with leukemic cell DNA compared with normal DNA. BM cell aspirations almost always contain residual normal cells in addition to the leukemic cells with variations dependent on the stage and patchyness of the disease. Unfortunately, it is impossible to determine the minimal number of leukemic cells in bone marrow needed to give positive plasma PCR results. We assume that even extramedullary leukemic cells may provide DNA that can be detected in the analyzing plasma DNA. Data from studies of solid tumors also support the concept that plasma/serum samples have a tendency to be enriched by the tumor-specific DNA. 26, 27 This enrichment is due perhaps to the high turnover of the tumor cells compared with relative normal tissue. Plasma/serum samples in patients with leukemia may be more enriched by leukemia-specific DNA than plasma in solid tumors because cells are more in contact with circulating blood. Four of our cases showed a wild-type band smaller than the ITD band, which is consistent with the hemizygous/homozygous phenotype. LOH was determined in the four samples, but only two showed LOH on one site of chromosome 13(D13S1265), which is consistent with the hemizygous phenotype. The lack of LOH in the Representative example illustrating that plasma DNA (a) has more intense ITD band than BM cells DNA (b) from the same patient. -M2  75%  69%  M3  4%  5%  M4-M5  21%  21%  M6-M7  0%  RA/RARS  13%  RAEB  13%  RAEB-T  74%  5% CR, complete remission; WBC, white cell count; HGB, hemoglobin; AHD, antecedent hematologic disease; FAB, French-American-British classification; RA, refractory anemia; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-T, refractory anemia with excess blasts in transformation.
other two cases may be due to homozygous ITD or due to the fact that our microsatellite markers are unable to detect LOH because they are outside the deleted region. One case showed two ITD bands consistent with ITD in both alleles. It is possible that the second band represents further duplication in the first duplication. However, this is unlikely because there is no reported selective advantage for increasing the magnitude of the duplication and if it has selective advantage, the majority of the leukemic cells would have it and we would not see the intense smaller duplication band. As expected, FLT3 ITD was detected in both BM DNA and PB plasma DNA in 21% of the AML cases. Only one of the 16 MDS cases had FLT3 ITD and none of the ALL cases demonstrated FLT3 ITD. A recent study by Whitman et al 25 demonstrated the significance of FLT3 ITD with loss of the wildtype in the survival of patients younger than 60 years of age.
Leukemia
In our study, FLT3 ITD was associated with a substantially shorter survival duration when only patients younger than 50 years old (n = 48 cases) were considered regardless of their cytogenetics. When the same patients were compared with those with FLT3 ITD hemizygous or homozygous phenotype, the latter patients had even shorter survival durations, confirming the finding of Whitman et al. 25 However, total loss of the wild-type was not observed in our PCR products, but a weaker wild-type was; hence, the hemizygous/homozygous phenotype. This is most likely due to the high sensitivity of capillary electrophoresis. Furthermore, when we analyzed patients younger than 60 years old we found no correlation between the presence of ITD and survival duration; however, we did find a correlation between the presence of ITD and survival in patients younger than 50 years old. However, the number of cases studied here is too small and these findings need to be confirmed by studying a large number of patients. Our study has demonstrated, as have other studies, that FLT3 ITD is associated with higher WBC counts. The WBC counts in patients positive for FLT3 ITD were higher than those in patients negative for FLT3 ITD, and it was highest in the groups with hemizygous or homozygous phenotype.
In conclusion, PB plasma DNA is a reliable alternative to BM cell DNA for the detection of FLT3 ITD, and PB plasma DNA is possibly more reliable in detecting the FLT3 ITD hemizygous/homozygous phenotype. PB plasma DNA has the potential to be used in monitoring disease progression and therapeutic efficacy. Further studies are needed to explore this possibility.
